Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 711

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Therapeutic application of histone deacetylase inhibitors for central nervous system disorders

Kazantsev, Aleksey G., Thompson, Leslie M.·2008·Nature Reviews Drug Discovery
DOI 10.1038/nrd2681
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrd2681

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Research works printed but not linked: 181

  1. Hardy, J. & Orr, H. The genetics of neurodegenerative diseases. J. Neurochem. 97, 1690–1699 (2006). · DOI
  2. Coppede, F., Mancuso, M., Siciliano, G., Migliore, L. & Murri, L. Genes and the environment in neurodegeneration. Biosci. Rep. 26, 341–367 (2006). · DOI
  3. Dosunmu, R., Wu, J., Basha, M. R. & Zawia, N. H. Environmental and dietary risk factors in Alzheimer's disease. Expert Rev. Neurother. 7, 887–900 (2007). · DOI
  4. Krichmar, J. L. & Edelman, G. M. Brain-based devices for the study of nervous systems and the development of intelligent machines. Artif. Life 11, 63–77 (2005). · DOI · Paper page
  5. Broderick, D. F. Neuroimaging in neuropsychiatry. Psychiatr. Clin. North Am. 28, 549–566 (2005). · DOI
  6. Gallen, C. C. Strategic challenges in neurotherapeutic pharmaceutical development. NeuroRx 1, 165–180 (2004). · doi:10.1602/neurorx.1.1.165
  7. Lipinski, C. & Hopkins, A. Navigating chemical space for biology and medicine. Nature 432, 855–861 (2004). · DOI · Paper page
  8. Davie, J. R. & Spencer, V. A. Control of histone modifications. J. Cell. Biochem. 75 (Suppl. 32), 141–148 (1999). · DOI
  9. Langley, B., Gensert, J. M., Beal, M. F. & Ratan, R. R. Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents. Curr. Drug Targets CNS Neurol. Disord. 4, 41–50 (2005). · DOI · Paper page
  10. Bhaumik, S. R., Smith, E. & Shilatifard, A. Covalent modifications of histones during development and disease pathogenesis. Nature Struct. Mol. Biol. 14, 1008–1016 (2007). · DOI · Paper page
  11. Michan, S. & Sinclair, D. Sirtuins in mammals: insights into their biological function. Biochem. J. 404, 1–13 (2007). · DOI · Paper page
  12. Kim, S. C. et al. Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol. Cell 23, 607–618 (2006). · DOI · Paper page
  13. Kruhlak, M. J. et al. Regulation of global acetylation in mitosis through loss of histone acetyltransferases and deacetylases from chromatin. J. Biol. Chem. 276, 38307–38319 (2001). · DOI · Paper page
  14. Neely, K. E. & Workman, J. L. The complexity of chromatin remodeling and its links to cancer. Biochim. Biophys. Acta 1603, 19–29 (2002).
  15. Sun, J. M., Spencer, V. A., Chen, H. Y., Li, L. & Davie, J. R. Measurement of histone acetyltransferase and histone deacetylase activities and kinetics of histone acetylation. Methods 31, 12–23 (2003). · DOI
  16. Bolden, J. E., Peart, M. J. & Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors. Nature Rev. Drug Discov. 5, 769–784 (2006). · DOI · Paper page
  17. Gregoretti, I. V., Lee, Y. M. & Goodson, H. V. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J. Mol. Biol. 338, 17–31 (2004). · DOI · Paper page
  18. Marsoni, S., Damia, G. & Camboni, G. A work in progress: the clinical development of histone deacetylase inhibitors. Epigenetics 3, 164–171 (2008). · DOI
  19. Abel, T. & Zukin, R. S. Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. Curr. Opin. Pharmacol. 8, 57–64 (2008). · DOI · Paper page
  20. Morrison, B. E., Majdzadeh, N. & D'Mello, S. R. Histone deacetylases: focus on the nervous system. Cell. Mol. Life Sci. 64, 2258–2269 (2007). · DOI
  21. Hahnen, E. et al. Histone deacetylase inhibitors: possible implications for neurodegenerative disorders. Expert Opin. Investig. Drugs 17, 169–184 (2008). · DOI · Paper page
  22. Butler, R. & Bates, G. P. Histone deacetylase inhibitors as therapeutics for polyglutamine disorders. Nature Rev. Neurosci. 7, 784–796 (2006). · DOI · Paper page
  23. Thiagalingam, S. et al. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann. NY Acad. Sci. 983, 84–100 (2003). · DOI · Paper page
  24. Wang, S., Yan-Neale, Y., Zeremski, M. & Cohen, D. Transcription regulation by histone deacetylases. Novartis Found. Symp. 259, 238–245 (2004). · DOI
  25. Yang, W. M., Tsai, S. C., Wen, Y. D., Fejer, G. & Seto, E. Functional domains of histone deacetylase-3. J. Biol. Chem. 277, 9447–9454 (2002). · DOI · Paper page
  26. Laherty, C. D. et al. Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression. Cell 89, 349–356 (1997). · DOI · Paper page
  27. Wen, Y. D. et al. The histone deacetylase-3 complex contains nuclear receptor corepressors. Proc. Natl Acad. Sci. USA 97, 7202–7207 (2000). · DOI · Paper page
  28. Martin, M., Kettmann, R. & Dequiedt, F. Class IIa histone deacetylases: regulating the regulators. Oncogene 26, 5450–5467 (2007). · DOI · Paper page
  29. Majdzadeh, N., Morrison, B. E. & D'Mello, S. R. Class IIA HDACs in the regulation of neurodegeneration. Front. Biosci. 13, 1072–1082 (2008). · DOI
  30. Zhang, C. L., McKinsey, T. A. & Olson, E. N. Association of class II histone deacetylases with heterochromatin protein 1: potential role for histone methylation in control of muscle differentiation. Mol. Cell. Biol. 22, 7302–7312 (2002). · DOI · Paper page
  31. Jones, P. et al. Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases. Bioorg. Med. Chem. Lett. 18, 1814–1819 (2008). · DOI
  32. Wang, A. H. & Yang, X. J. Histone deacetylase 4 possesses intrinsic nuclear import and export signals. Mol. Cell. Biol. 21, 5992–6005 (2001). · DOI · Paper page
  33. Bertos, N. R., Wang, A. H. & Yang, X. J. Class II histone deacetylases: structure, function, and regulation. Biochem. Cell Biol. 79, 243–252 (2001). · doi:10.1139/o01-032 · Paper page
  34. Zhang, C. L., McKinsey, T. A. & Olson, E. N. The transcriptional corepressor MITR is a signal-responsive inhibitor of myogenesis. Proc. Natl Acad. Sci. USA 98, 7354–7359 (2001). · DOI
  35. Petrie, K. et al. The histone deacetylase 9 gene encodes multiple protein isoforms. J. Biol. Chem. 278, 16059–16072 (2003). · DOI
  36. Grozinger, C. M. & Schreiber, S. L. Regulation of histone deacetylase 4 and 5 and transcriptional activity by 14-3-3-dependent cellular localization. Proc. Natl Acad. Sci. USA 97, 7835–7840 (2000). · DOI · Paper page
  37. Kao, H. Y. et al. Mechanism for nucleocytoplasmic shuttling of histone deacetylase 7. J. Biol. Chem. 276, 47496–47507 (2001). · DOI · Paper page
  38. Ellis, J. J. et al. CaM kinase IIdeltaC phosphorylation of 14-3-3β in vascular smooth muscle cells: activation of class II HDAC repression. Mol. Cell Biochem. 242, 153–161 (2003). · DOI
  39. Tong, J. J., Liu, J., Bertos, N. R. & Yang, X. J. Identification of HDAC10, a novel class II human histone deacetylase containing a leucine-rich domain. Nucleic Acids Res. 30, 1114–1123 (2002). · DOI · Paper page
  40. Liu, H., Hu, Q., Kaufman, A., D'Ercole, A. J. & Ye, P. Developmental expression of histone deacetylase 11 in the murine brain. J. Neurosci. Res. 86, 537–543 (2008). · DOI
  41. Gan, L. & Mucke, L. Paths of convergence: sirtuins in aging and neurodegeneration. Neuron 58, 10–14 (2008). · DOI · Paper page
  42. Sauve, A. A., Wolberger, C., Schramm, V. L. & Boeke, J. D. The biochemistry of sirtuins. Annu. Rev. Biochem. 75, 435–465 (2006). · DOI · Paper page
  43. North, B. J., Schwer, B., Ahuja, N., Marshall, B. & Verdin, E. Preparation of enzymatically active recombinant class III protein deacetylases. Methods 36, 338–345 (2005). · DOI
  44. Denu, J. M. The Sir 2 family of protein deacetylases. Curr. Opin. Chem. Biol. 9, 431–440 (2005). · DOI · Paper page
  45. Vaquero, A. et al. Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin. Mol. Cell 16, 93–105 (2004). · DOI · Paper page
  46. Senawong, T., Peterson, V. J. & Leid, M. BCL11A-dependent recruitment of SIRT1 to a promoter template in mammalian cells results in histone deacetylation and transcriptional repression. Arch. Biochem. Biophys. 434, 316–325 (2005). · DOI
  47. Tanno, M., Sakamoto, J., Miura, T., Shimamoto, K. & Horio, Y. Nucleocytoplasmic shuttling of the NAD+-dependent histone deacetylase SIRT1. J. Biol. Chem. 282, 6823–6832 (2007). · DOI · Paper page
  48. North, B. J., Marshall, B. L., Borra, M. T., Denu, J. M. & Verdin, E. The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol. Cell 11, 437–444 (2003). · DOI · Paper page
  49. Southwood, C. M., Peppi, M., Dryden, S., Tainsky, M. A. & Gow, A. Microtubule deacetylases, SirT2 and HDAC6, in the nervous system. Neurochem. Res. 32, 187–195 (2007). · DOI
  50. Vaquero, A. et al. SirT2 is a histone deacetylase with preference for histone H4 Lys16 during mitosis. Genes Dev. 20, 1256–1261 (2006). · DOI · Paper page
  51. Schwer, B., North, B. J., Frye, R. A., Ott, M. & Verdin, E. The human silent information regulator (Sir)2 homologue hSIRT3 is a mitochondrial nicotinamide adenine dinucleotide-dependent deacetylase. J. Cell Biol. 158, 647–657 (2002). · DOI · Paper page
  52. Schwer, B., Bunkenborg, J., Verdin, R. O., Andersen, J. S. & Verdin, E. Reversible lysine acetylation controls the activity of the mitochondrial enzyme acetyl-CoA synthetase 2. Proc. Natl Acad. Sci. USA 103, 10224–10229 (2006). · DOI · Paper page
  53. Hallows, W. C., Lee, S. & Denu, J. M. Sirtuins deacetylate and activate mammalian acetyl-CoA synthetases. Proc. Natl Acad. Sci. USA 103, 10230–10235 (2006). · DOI · Paper page
  54. Michishita, E., Park, J. Y., Burneskis, J. M., Barrett, J. C. & Horikawa, I. Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol. Biol. Cell 16, 4623–4635 (2005). · DOI · Paper page
  55. Broide, R. S. et al. Distribution of histone deacetylases 1–11 in the rat brain. J. Mol. Neurosci. 31, 47–58 (2007). · DOI · Paper page
  56. Lu, J., McKinsey, T. A., Zhang, C. L. & Olson, E. N. Regulation of skeletal myogenesis by association of the MEF2 transcription factor with class II histone deacetylases. Mol. Cell 6, 233–244 (2000). · DOI · Paper page
  57. Zhang, C. L., McKinsey, T. A., Lu, J. R. & Olson, E. N. Association of COOH-terminal-binding protein (CtBP) and MEF2-interacting transcription repressor (MITR) contributes to transcriptional repression of the MEF2 transcription factor. J. Biol. Chem. 276, 35–39 (2001). · DOI · Paper page
  58. Mao, Z., Bonni, A., Xia, F., Nadal-Vicens, M. & Greenberg, M. E. Neuronal activity-dependent cell survival mediated by transcription factor MEF2. Science 286, 785–790 (1999). · DOI · Paper page
  59. Zhou, X., Richon, V. M., Rifkind, R. A. & Marks, P. A. Identification of a transcriptional repressor related to the noncatalytic domain of histone deacetylases 4 and 5. Proc. Natl Acad. Sci. USA 97, 1056–1061 (2000). · DOI · Paper page
  60. Chawla, S., Vanhoutte, P., Arnold, F. J., Huang, C. L. & Bading, H. Neuronal activity-dependent nucleocytoplasmic shuttling of HDAC4 and HDAC5. J. Neurochem. 85, 151–159 (2003). · DOI · Paper page
  61. Belfield, J. L., Whittaker, C., Cader, M. Z. & Chawla, S. Differential effects of Ca2+ and cAMP on transcription mediated by MEF2D and cAMP-response element-binding protein in hippocampal neurons. J. Biol. Chem. 281, 27724–27732 (2006). · DOI
  62. Bolger, T. A. & Yao, T. P. Intracellular trafficking of histone deacetylase 4 regulates neuronal cell death. J. Neurosci. 25, 9544–9553 (2005). · DOI · Paper page
  63. Berdeaux, R. et al. SIK1 is a class II HDAC kinase that promotes survival of skeletal myocytes. Nature Med. 13, 597–603 (2007). · DOI · Paper page
  64. Kawaguchi, Y. et al. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115, 727–738 (2003). This provided a new role for HDAC6 that led to work by Kopito and others to show that HDAC6 and microtubules are involved in the clearance of protein aggregates in neurodegenerative disease ( J. Biol Chem. 280, 40282–40292; 2005). · DOI · Paper page
  65. Murphy, P. J., Morishima, Y., Kovacs, J. J., Yao, T. P. & Pratt, W. B. Regulation of the dynamics of hsp90 action on the glucocorticoid receptor by acetylation/deacetylation of the chaperone. J. Biol. Chem. 280, 33792–33799 (2005). · DOI · Paper page
  66. Li, W. et al. Sirtuin 2, a mammalian homolog of yeast silent information regulator-2 longevity regulator, is an oligodendroglial protein that decelerates cell differentiation through deacetylating α-tubulin. J. Neurosci. 27, 2606–2616 (2007). · DOI · Paper page
  67. Chen, D. & Guarente, L. SIR2: a potential target for calorie restriction mimetics. Trends Mol. Med. 13, 64–71 (2007). · DOI · Paper page
  68. Bishop, N. A. & Guarente, L. Genetic links between diet and lifespan: shared mechanisms from yeast to humans. Nature Rev. Genet. 8, 835–844 (2007). · DOI · Paper page
  69. Sakamoto, J., Miura, T., Shimamoto, K. & Horio, Y. Predominant expression of Sir2alpha, an NAD-dependent histone deacetylase, in the embryonic mouse heart and brain. FEBS Lett. 556, 281–286 (2004). · DOI · Paper page
  70. Milne, J. C. & Denu, J. M. The Sirtuin family: therapeutic targets to treat diseases of aging. Curr. Opin. Chem. Biol. 12, 11–17 (2008). · DOI · Paper page
  71. Outeiro, T. F., Marques, O. & Kazantsev, A. Therapeutic role of sirtuins in neurodegenerative disease. Biochim. Biophys. Acta 1782, 363–369 (2008). · DOI
  72. Oike, Y. et al. Truncated CBP protein leads to classical Rubinstein–Taybi syndrome phenotypes in mice: implications for a dominant-negative mechanism. Hum. Mol. Genet. 8, 387–396 (1999). · DOI · Paper page
  73. Alarcon, J. M. et al. Chromatin acetylation, memory, and LTP are impaired in CBP+/− mice: a model for the cognitive deficit in Rubinstein–Taybi syndrome and its amelioration. Neuron 42, 947–959 (2004). · DOI · Paper page
  74. Barco, A. The Rubinstein–Taybi syndrome: modeling mental impairment in the mouse. Genes Brain Behav. 6 (Suppl. 1), 32–39 (2007). · DOI
  75. Vecsey, C. G. et al. Histone deacetylase inhibitors enhance memory and synaptic plasticity via CREB:CBP-dependent transcriptional activation. J. Neurosci. 27, 6128–6140 (2007). This important paper demonstrates the effects of HDAC inhibitors on restoration of memory loss by enhancing transcriptional expression of specific neuronal genes and suggests benefits of HDAC treatment for Rubinstein–Taybi syndrome. · DOI · Paper page
  76. Schroeder, F. A., Lin, C. L., Crusio, W. E. & Akbarian, S. Antidepressant-like effects of the histone deacetylase inhibitor, sodium butyrate, in the mouse. Biol. Psychiatry 62, 55–64 (2007). · DOI · Paper page
  77. LaSalle, J. M. The odyssey of MeCP2 and parental imprinting. Epigenetics 2, 5–10 (2007). · DOI
  78. Pandolfo, M. Friedreich's ataxia: clinical aspects and pathogenesis. Semin. Neurol. 19, 311–321 (1999). · DOI
  79. Rai, M. et al. HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model. PLoS ONE 3, e1958 (2008). · DOI · Paper page
  80. O'Donnell, W. T. & Warren, S. T. A decade of molecular studies of fragile X syndrome. Annu. Rev. Neurosci. 25, 315–338 (2002). · DOI · Paper page
  81. Garber, K., Smith, K. T., Reines, D. & Warren, S. T. Transcription, translation and fragile X syndrome. Curr. Opin. Genet. Dev. 16, 270–275 (2006). · DOI
  82. Chandler, S. P., Kansagra, P. & Hirst, M. C. Fragile X (CGG)n repeats induce a transcriptional repression in cis upon a linked promoter: evidence for a chromatin mediated effect. BMC Mol. Biol. 4, 3 (2003). · DOI
  83. Chiurazzi, P. et al. Synergistic effect of histone hyperacetylation and DNA demethylation in the reactivation of the FMR1 gene. Hum. Mol. Genet. 8, 2317–2323 (1999). · DOI · Paper page
  84. Pietrobono, R. et al. Quantitative analysis of DNA demethylation and transcriptional reactivation of the FMR1 gene in fragile X cells treated with 5-azadeoxycytidine. Nucleic Acids Res. 30, 3278–3285 (2002). · DOI
  85. Biacsi, R., Kumari, D. & Usdin, K. SIRT1 inhibition alleviates gene silencing in fragile X mental retardation syndrome. PLoS Genet. 4, e1000017 (2008). · DOI
  86. Avila, A. M. et al. Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J. Clin. Invest. 117, 659–671 (2007). · DOI · Paper page
  87. Riessland, M., Brichta, L., Hahnen, E. & Wirth, B. The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells. Hum. Genet. 120, 101–110 (2006). · DOI
  88. Hirtz, D. et al. Challenges and opportunities in clinical trials for spinal muscular atrophy. Neurology 65, 1352–1357 (2005). · DOI
  89. Kernochan, L. E. et al. The role of histone acetylation in SMN gene expression. Hum. Mol. Genet. 14, 1171–1182 (2005). · DOI · Paper page
  90. Hahnen, E. et al. In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy. J. Neurochem. 98, 193–202 (2006). · DOI
  91. Ryu, H. et al. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J. Neurochem. 93, 1087–1098 (2005). · DOI · Paper page
  92. Rouaux, C. et al. Sodium valproate exerts neuroprotective effects in vivo through CREB-binding protein-dependent mechanisms but does not improve survival in an amyotrophic lateral sclerosis mouse model. J. Neurosci. 27, 5535–5545 (2007). · DOI · Paper page
  93. Minamiyama, M. et al. Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Hum. Mol. Genet. 13, 1183–1192 (2004). · DOI · Paper page
  94. Orr, H. T. & Zoghbi, H. Y. Trinucleotide repeat disorders. Annu. Rev. Neurosci. 30, 575–621 (2007). · DOI · Paper page
  95. Steffan, J. S. et al. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl Acad. Sci. USA 97, 6763–6768 (2000). · DOI · Paper page
  96. Luthi-Carter, R. et al. Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects. Hum. Mol. Genet. 11, 1927–1937 (2002). · DOI · Paper page
  97. Serra, H. G. et al. Gene profiling links SCA1 pathophysiology to glutamate signaling in Purkinje cells of transgenic mice. Hum. Mol. Genet. 13, 2535–2543 (2004). · DOI · Paper page
  98. Tsai, C. C. et al. Ataxin 1, a SCA1 neurodegenerative disorder protein, is functionally linked to the silencing mediator of retinoid and thyroid hormone receptors. Proc. Natl Acad. Sci. USA 101, 4047–4052 (2004). · DOI
  99. Helmlinger, D., Tora, L. & Devys, D. Transcriptional alterations and chromatin remodeling in polyglutamine diseases. Trends Genet. 22, 562–570 (2006). · DOI
  100. Nakamura, K. et al. SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein. Hum. Mol. Genet. 10, 1441–1448 (2001). · DOI · Paper page
  101. La Spada, A. R., Wilson, E. M., Lubahn, D.B., Harding, A. E. & Fischbeck, K. H. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352, 77–79 (1991). · DOI · Paper page
  102. Helmlinger, D. et al. Ataxin-7 is a subunit of GCN5 histone acetyltransferase-containing complexes. Hum. Mol. Genet. 13, 1257–1265 (2004). · DOI · Paper page
  103. Evert, B. O. et al. Ataxin-3 represses transcription via chromatin binding, interaction with histone deacetylase 3, and histone deacetylation. J. Neurosci. 26, 11474–11486 (2006). · DOI · Paper page
  104. Hockly, E. et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl Acad. Sci. USA 100, 2041–2046 (2003). This paper showed the benefits of a HDAC inhibitor (voronistat) in a mouse model of neurodegeneration. · DOI · Paper page
  105. Ferrante, R. J. et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J. Neurosci. 23, 9418–9427 (2003). · DOI · Paper page
  106. Thomas, E. A. et al. The histone deacetylase inhibitor, HDACi 4b, ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc. Natl Acad. Sci. USA (in the press).
  107. Sadri-Vakili, G. & Cha, J. H. Histone deacetylase inhibitors: a novel therapeutic approach to Huntington's disease (complex mechanism of neuronal death). Curr. Alzheimer Res. 3, 403–408 (2006). · DOI
  108. Bates, E. A., Victor, M., Jones, A. K., Shi, Y. & Hart, A. C. Differential contributions of Caenorhabditis elegans histone deacetylases to huntingtin polyglutamine toxicity. J. Neurosci. 26, 2830–2838 (2006). · DOI
  109. Pallos, J. et al. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. Hum. Mol. Genet. 1 Sep 2008 (doi:10.1093/hmg/ddn273). · DOI · Paper page
  110. Fernandez-Funez, P. et al. Identification of genes that modify ataxin-1-induced neurodegeneration. Nature 408, 101–106 (2000). · DOI · Paper page
  111. Parker, J. A. et al. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nature Genet. 37, 349–350 (2005). This paper provides genetic and pharmacological evidence relating to possible the protective effects of SIRT1 activation in in vivo neurodegeneration models. · DOI · Paper page
  112. Shao, J. & Diamond, M. I. Polyglutamine diseases: emerging concepts in pathogenesis and therapy. Hum. Mol. Genet. 16 (Spec. No. 2), R115–R123 (2007). · DOI · Paper page
  113. Imarisio, S. et al. Huntington's disease: from pathology and genetics to potential therapies. Biochem. J. 412, 191–209 (2008). · DOI · Paper page
  114. Ross, C. A. & Thompson, L. M. Transcription meets metabolism in neurodegeneration. Nature Med. 12, 1239–1241 (2006). · DOI
  115. Kazantsev, A. G. & Hersch, S. M. Drug targeting of dysregulated transcription in Huntington's disease. Prog. Neurobiol. 83, 249–259 (2007). · DOI
  116. Oliveira, J. M. et al. Mitochondrial-dependent Ca2+ handling in Huntington's disease striatal cells: effect of histone deacetylase inhibitors. J. Neurosci. 26, 11174–11186 (2006). · DOI
  117. Dompierre, J. P. et al. Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation. J. Neurosci. 27, 3571–3583 (2007). · DOI · Paper page
  118. Berke, S. J. & Paulson, H. L. Protein aggregation and the ubiquitin proteasome pathway: gaining the UPPer hand on neurodegeneration. Curr. Opin. Genet. Dev. 13, 253–261 (2003). · DOI · Paper page
  119. Rubinsztein, D. C. et al. Autophagy and its possible roles in nervous system diseases, damage and repair. Autophagy 1, 11–22 (2005). · DOI · Paper page
  120. Outeiro, T. F. et al. Sirtuin 2 inhibitors rescue α-synuclein-mediated toxicity in models of Parkinson's disease. Science 317, 516–519 (2007). Provides evidence regarding the feasibility of a novel treatment approach for neurodegeneration using selective inhibitors of SIRT2. · DOI · Paper page
  121. Raine, C. S. Multiple sclerosis: immune system molecule expression in the central nervous system. J. Neuropathol. Exp. Neurol. 53, 328–337 (1994). · DOI · Paper page
  122. Dheen, S. T., Kaur, C. & Ling, E. A. Microglial activation and its implications in the brain diseases. Curr. Med. Chem. 14, 1189–1197 (2007). · DOI · Paper page
  123. Camelo, S. et al. Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. J. Neuroimmunol. 164, 10–21 (2005). · DOI · Paper page
  124. Gray, S. G. & Dangond, F. Rationale for the use of histone deacetylase inhibitors as a dual therapeutic modality in multiple sclerosis. Epigenetics 1, 67–75 (2006). · DOI
  125. Ren, M., Leng, Y., Jeong, M., Leeds, P. R. & Chuang, D. M. Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J. Neurochem. 89, 1358–1367 (2004). · DOI · Paper page
  126. Faraco, G. et al. Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain. Mol. Pharmacol. 70, 1876–1884 (2006). · DOI · Paper page
  127. Kim, H. J. et al. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J. Pharmacol. Exp. Ther. 321, 892–901 (2007). · DOI · Paper page
  128. Langley, B. et al. Pulse inhibition of histone deacetylases induces complete resistance to oxidative death in cortical neurons without toxicity and reveals a role for cytoplasmic p21waf1/cip1 in cell cycle-independent neuroprotection. J. Neurosci. 28, 163–176 (2008). · DOI
  129. Chuang, D. M. The antiapoptotic actions of mood stabilizers: molecular mechanisms and therapeutic potentials. Ann. NY Acad. Sci. 1053, 195–204 (2005). · DOI · Paper page
  130. Giorgini, F. et al. Histone deacetylase inhibition modulates kynurenine pathway activation in yeast, microglia, and mice expressing a mutant huntingtin fragment. J. Biol. Chem. 283, 7390–7400 (2008). · DOI
  131. Nixon, R. A. Niemann–Pick type C disease and Alzheimer's disease: the APP-endosome connection fattens up. Am. J. Pathol. 164, 757–761 (2004). · DOI
  132. Hooper, N. M. Roles of proteolysis and lipid rafts in the processing of the amyloid precursor protein and prion protein. Biochem. Soc. Trans. 33, 335–338 (2005). · DOI
  133. Roff, C. F. et al. Type C Niemann–Pick disease: use of hydrophobic amines to study defective cholesterol transport. Dev. Neurosci. 13, 315–319 (1991). · DOI
  134. Vance, J. E. Lipid imbalance in the neurological disorder, Niemann–Pick C disease. FEBS Lett. 580, 5518–5524 (2006). · DOI
  135. Garver, W. S. & Heidenreich, R. A. The Niemann–Pick C proteins and trafficking of cholesterol through the late endosomal/lysosomal system. Curr. Mol. Med. 2, 485–505 (2002). · DOI
  136. Mukherjee, S. & Maxfield, F. R. Lipid and cholesterol trafficking in NPC. Biochim. Biophys. Acta 1685, 28–37 (2004). · DOI · Paper page
  137. Karten, B., Vance, D. E., Campenot, R. B. & Vance, J. E. Cholesterol accumulates in cell bodies, but is decreased in distal axons, of Niemann–Pick C1-deficient neurons. J. Neurochem. 83, 1154–1163 (2002). · DOI
  138. Karten, B., Vance, D. E., Campenot, R. B. & Vance, J. E. Trafficking of cholesterol from cell bodies to distal axons in Niemann Pick C1-deficient neurons. J. Biol. Chem. 278, 4168–4175 (2003). · DOI
  139. Kim, S. J., Lee, B. H., Lee, Y. S. & Kang, K. S. Defective cholesterol traffic and neuronal differentiation in neural stem cells of Niemann–Pick type C disease improved by valproic acid, a histone deacetylase inhibitor. Biochem. Biophys. Res. Commun. 360, 593–599 (2007). · DOI
  140. Li, X. et al. SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol. Cell 28, 91–106 (2007). · DOI · Paper page
  141. Valenza, M. et al. Cholesterol biosynthesis pathway is disturbed in YAC128 mice and is modulated by huntingtin mutation. Hum. Mol. Genet. 16, 2187–2198 (2007). · DOI · Paper page
  142. Valenza, M. et al. Progressive dysfunction of the cholesterol biosynthesis pathway in the R6/2 mouse model of Huntington's disease. Neurobiol. Dis. 28, 133–142 (2007). · DOI · Paper page
  143. Trushina, E. et al. Mutant huntingtin inhibits clathrin-independent endocytosis and causes accumulation of cholesterol in vitro and in vivo. Hum. Mol. Genet. 15, 3578–3591 (2006). · DOI
  144. Bordone, L. & Guarente, L. Calorie restriction, SIRT1 and metabolism: understanding longevity. Nature Rev. Mol. Cell Biol. 6, 298–305 (2005). · DOI · Paper page
  145. Sinclair, D. A. Toward a unified theory of caloric restriction and longevity regulation. Mech. Ageing Dev. 126, 987–1002 (2005). · DOI · Paper page
  146. Bordone, L. et al. SIRT1 transgenic mice show phenotypes resembling calorie restriction. Aging Cell 6, 759–767 (2007). · DOI · Paper page
  147. Guarente, L. Sirtuins in aging and disease. Cold Spring Harb. Symp. Quant. Biol. 72, 483–488 (2007). · DOI · Paper page
  148. Baur, J. A. & Sinclair, D. A. Therapeutic potential of resveratrol: the in vivo evidence. Nature Rev. Drug Discov. 5, 493–506 (2006). · DOI · Paper page
  149. Catoire, H. et al. Sirtuin inhibition protects from the polyalanine muscular dystrophy protein PABPN1. Hum. Mol. Genet. 17, 2108–2117 (2008). · DOI
  150. Li, Y., Xu, W., McBurney, M. W. & Longo, V. D. SirT1 inhibition reduces IGF-I/IRS-2/Ras/ERK1/2 signaling and protects neurons. Cell. Metab. 8, 38–48 (2008). · DOI · Paper page
  151. Jung, M. Inhibitors of histone deacetylase as new anticancer agents. Curr. Med. Chem. 8, 1505–1511 (2001). · DOI · Paper page
  152. Vigushin, D. M. et al. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin. Cancer Res. 7, 971–976 (2001).
  153. Wang, C. et al. Histone acetylation and the cell-cycle in cancer. Front. Biosci. 6, D610–D629 (2001). · DOI
  154. Secrist, J. P., Zhou, X. & Richon, V. M. HDAC inhibitors for the treatment of cancer. Curr. Opin. Investig. Drugs 4, 1422–1427 (2003).
  155. Mai, A. et al. Synthesis and biological evaluation of 2-, 3-, and 4-acylaminocinnamyl-N-hydroxyamides as novel synthetic HDAC inhibitors. Med. Chem. 1, 245–254 (2005). · doi:10.2174/1573406053765431
  156. Yoshida, M. et al. Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother. Pharmacol. 48 (Suppl. 1), S20–S26 (2001). · DOI · Paper page
  157. Lu, Q. et al. Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J. Med. Chem. 47, 467–474 (2004). · DOI
  158. Liu, T., Kapustin, G. & Etzkorn, F. A. Design and synthesis of a potent histone deacetylase inhibitor. J. Med. Chem. 50, 2003–2006 (2007). · DOI
  159. Curtin, M. & Glaser, K. Histone deacetylase inhibitors: the Abbott experience. Curr. Med. Chem. 10, 2373–2392 (2003). · DOI
  160. Khan, N. et al. Determination of the class and isoform selectivity of small molecule HDAC inhibitors. Biochem. J. 409, 581–589 (2008). · DOI · Paper page
  161. Khan, N. et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem. J. 409, 581–589 (2008). · DOI · Paper page
  162. Glaser, K. B. et al. Differential protein acetylation induced by novel histone deacetylase inhibitors. Biochem. Biophys. Res. Commun. 325, 683–690 (2004). · DOI
  163. Mai, A. et al. Exploring the connection unit in the HDAC inhibitor pharmacophore model: novel uracil-based hydroxamates. Bioorg Med. Chem. Lett. 15, 4656–4661 (2005). · DOI
  164. Perez-Balado, C. et al. Bispyridinium dienes: histone deacetylase inhibitors with selective activities. J. Med. Chem. 50, 2497–2505 (2007). · DOI
  165. Arts, J. et al. R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies. Br. J. Cancer 97, 1344–1353 (2007). · DOI
  166. Haggarty, S. J., Koeller, K. M., Wong, J. C., Butcher, R. A. & Schreiber, S. L. Multidimensional chemical genetic analysis of diversity-oriented synthesis-derived deacetylase inhibitors using cell-based assays. Chem. Biol. 10, 383–396 (2003). · DOI · Paper page
  167. Mai, A. et al. Discovery of (aryloxopropenyl)pyrrolyl hydroxyamides as selective inhibitors of class IIa histone deacetylase homologue HD1-A. J. Med. Chem. 46, 4826–4829 (2003). · DOI
  168. Haggarty, S. J., Koeller, K. M., Wong, J. C., Grozinger, C. M. & Schreiber, S. L. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc. Natl Acad. Sci. USA 100, 4389–4394 (2003). · DOI · Paper page
  169. Glaser, K. B. HDAC inhibitors: clinical update and mechanism-based potential. Biochem. Pharmacol. 74, 659–671 (2007). · DOI · Paper page
  170. Beckers, T. et al. Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int. J. Cancer 121, 1138–1148 (2007). · DOI · Paper page
  171. Hess-Stumpp, H., Bracker, T. U., Henderson, D. & Politz, O. MS-275, a potent orally available inhibitor of histone deacetylases — the development of an anticancer agent. Int. J. Biochem. Cell Biol. 39, 1388–1405 (2007). · DOI
  172. Hu, E. et al. Identification of novel isoform-selective inhibitors within class I histone deacetylases. J. Pharmacol. Exp. Ther. 307, 720–728 (2003). · DOI · Paper page
  173. Simonini, M. V. et al. The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases. Proc. Natl Acad. Sci. USA 103, 1587–1592 (2006). This important paper describes the application of HDAC inhibitors for the treatment of CNS disorders, using one of the first benzamide-based brain-permeable HDAC inhibitors developed. · DOI · Paper page
  174. Zhang, B. et al. HDAC inhibitor increases histone H3 acetylation and reduces microglia inflammatory response following traumatic brain injury in rats. Brain Res. 1226, 181–191 (2008). · DOI
  175. Marcotte, P. A. et al. Fluorescence assay of SIRT protein deacetylases using an acetylated peptide substrate and a secondary trypsin reaction. Anal. Biochem. 332, 90–99 (2004). · DOI
  176. Galletti, P. et al. Diverse effects of natural antioxidants on cyclosporin cytotoxicity in rat renal tubular cells. Nephrol. Dial. Transplant. 20, 1551–1558 (2005). · doi:10.1093/ndt/gfh846
  177. Grozinger, C. M., Chao, E. D., Blackwell, H. E., Moazed, D. & Schreiber, S. L. Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J. Biol. Chem. 276, 38837–38843 (2001). · DOI · Paper page
  178. Mai, A. et al. Design, synthesis, and biological evaluation of sirtinol analogues as class III histone/protein deacetylase (Sirtuin) inhibitors. J. Med. Chem. 48, 7789–7795 (2005). · DOI · Paper page
  179. Napper, A. D. et al. Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. J. Med. Chem. 48, 8045–8054 (2005). · DOI · Paper page
  180. Trapp, J. et al. Structure–activity studies on suramin analogues as inhibitors of NAD+-dependent histone deacetylases (Sirtuins). ChemMedChem 2, 1419–1431 (2007). · DOI · Paper page
  181. Pardridge, W. M. Brain drug development and brain drug targeting. Pharm. Res. 24, 1729–1732 (2007). · DOI

Cited by

See all 711

Metadata

Authors
Kazantsev, A. G., & Thompson, L. M.
Venue
Nature Reviews Drug Discovery
Publisher
Springer Science and Business Media LLC
Published
2008-10
Volume
7
Issue
10
Pages
854-868
ISSN
  • 1474-1776 (ISSN-L)
  • 1474-1784
DOI
10.1038/nrd2681
OpenAlex
W1996277745
Cited by
711
References
38
FWCI
2.73
Type
journal article
Language
en
Open access
closed
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. https://app.cochat.ai/papers/10.1038/nrd2681
The paper
Kazantsev, A. G., & Thompson, L. M. (2008). Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nature Reviews Drug Discovery. https://doi.org/10.1038/nrd2681

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.